Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 10/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 5/20 | 1.00 |
| ▸ | SERPINA6 | P08185 | 4/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | SHBG | P04278 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | KCNA1 | Q09470 | 1/20 | 1.00 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 1.00 |
| ▸ | FNTA | P49354 | 5/20 | 0.78 |
| ▸ | FNTB | P49356 | 5/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.78 |
| ▸ | BLM | P54132 | 2/20 | 0.78 |
| ▸ | MEN1 | O00255 | 2/20 | 0.78 |
| ▸ | AR | P10275 | 1/20 | 0.78 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cortisone SCHEMBL13332835 | 1.00 | HSD17B10 (1.00) | HSD17B10NR3C1SERPINA6TSHRLMNA | |
| Cortisone SCHEMBL13026135 | 1.00 | HSD17B10 (1.00) | HSD17B10NR3C1SERPINA6TSHRLMNA | |
| Cortisone SCHEMBL4888 | 1.00 | HSD17B10 (1.00) | HSD17B10NR3C1SERPINA6TSHRLMNA | |
| Cortisone SCHEMBL10089738 | 1.00 | HSD17B10 (1.00) | HSD17B10NR3C1SERPINA6TSHRLMNA | |
| Cortisone SCHEMBL9926754 | 1.00 | HSD17B10 (1.00) | HSD17B10NR3C1SERPINA6TSHRLMNA | |
| Cortisone SCHEMBL5082082 | 0.99 | HSD17B10 (0.98) | HSD17B10NR3C1SERPINA6TSHRLMNA | |
| Cortisone SCHEMBL28542114 | 0.99 | HSD17B10 (0.98) | HSD17B10NR3C1SERPINA6TSHRLMNA | |
| Cortisone SCHEMBL28537808 | 0.99 | HSD17B10 (0.98) | HSD17B10NR3C1SERPINA6TSHRLMNA | |
| Cortisone SCHEMBL5082086 | 0.99 | HSD17B10 (0.98) | HSD17B10NR3C1SERPINA6TSHRLMNA | |
| Cortisone SCHEMBL27538706 | 0.99 | HSD17B10 (0.98) | HSD17B10NR3C1SERPINA6TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114206884-B | Thienopyrimidine derivatives as ACC inhibitors and use thereof | 吉利德科学公司 | 2024-07-12 | — | — | CN | disclosed |
| EP-3426285-B1 | FORMULATIONS AND DOSES OF PEGYLATED URICASE | CARTESIAN THERAPEUTICS INC (US) | 2024-05-29 | — | — | EP | disclosed |
| US-20240100068-A1 | METHODS COMPRISING ADMINISTRATION OF A GLUCOCORTICOID RECEPTOR AGONIST AND AN INHIBITOR OF CALCINEURIN | CHENGDU ANTICANCER BIOSCIENCE LTD (CN) | 2024-03-28 | — | — | US | disclosed |
| US-20230119226-A1 | METHODS AND COMPOSITIONS RELATED TO COMBINED TREATMENT WITH ANTI-INFLAMMATORIES AND SYNTHETIC NANOCARRIERS COMPRISING AN IMMUNOSUPPRESSANT | SELECTA BIOSCIENCES, INC. (US) | 2023-04-20 | — | — | US | disclosed |
| US-20230107561-A1 | METHODS AND COMPOSITIONS RELATED TO COMBINED TREATMENT WITH ANTI-INFLAMMATORIES AND SYNTHETIC NANOCARRIERS COMPRISING AN IMMUNOSUPPRESSANT | SELECTA BIOSCIENCES, INC. (US) | 2023-04-06 | — | — | US | disclosed |
| EP-3980784-A1 | FORMULATIONS AND DOSES OF PEGYLATED URICASE | Selecta Biosciences, Inc. (US) | 2022-04-13 | — | — | EP | disclosed |
| US-20210187081-A1 | FORMULATIONS AND DOSES OF PEGYLATED URICASE | SELECTA BIOSCIENCES, INC. (US) | 2021-06-24 | — | — | US | disclosed |
| WO-2021110085-A1 | METHOD FOR ASSOCIATING WITH EXPRESSION LEVEL OF AKR1C3 ENZYME VIA CONTENT OF PROSTAGLANDIN, AND USE OF SCREENING FOR DRUG ADMINISTRATION | 深圳艾欣达伟医药科技有限公司 | 2021-06-10 | — | — | WO | disclosed |
| US-20200399628-A1 | FORMULATIONS AND DOSES OF PEGYLATED URICASE | SELECTA BIOSCIENCES, INC. (US) | 2020-12-24 | — | — | US | disclosed |
| US-20200390718-A1 | METHODS AND COMPOSITIONS FOR ATTENUATED ANTI-VIRAL TRANSFER VECTOR IMMUNE RESPONSE | SELECTA BIOSCIENCES, INC. (US) | 2020-12-17 | — | — | US | disclosed |
| EP-1143987-A4 | NATURAL COMPOSITION AND METHOD FOR THE TREATMENT OF SEXUAL DYSFUNCTION | DUCKETT MELVIN J (US) | 2004-09-22 | — | — | EP | disclosed |
| EP-1143987-A1 | NATURAL COMPOSITION AND METHOD FOR THE TREATMENT OF SEXUAL DYSFUNCTION | Duckett, Melvin J. (US) | 2001-10-17 | — | — | EP | disclosed |
| EP-1140021-A1 | IMPROVED FORMULATION FOR TOPICAL NON-INVASIVE APPLICATION IN VIVO | IDEA AG (DE) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000038653-A1 | IMPROVED FORMULATION FOR TOPICAL NON-INVASIVE APPLICATION IN VIVO | IDEA AG. (DE) | 2000-07-06 | — | — | WO | disclosed |
| WO-2000002573-A1 | NATURAL COMPOSITION AND METHOD FOR THE TREATMENT OF SEXUAL DYSFUNCTION | DUCKETT MELVIN J (US) | 2000-01-20 | — | — | WO | disclosed |
| EP-0155943-A1 | A METHOD OF DETERMINING CHANGES OCCURRING IN CARTILAGE | PHARMACIA AB (SE) | 1985-10-02 | — | — | EP | disclosed |
| WO-1985001353-A1 | A METHOD OF DETERMINING CHANGES OCCURRING IN CARTILAGE | PHARMACIA AB (SE) | 1985-03-28 | — | — | WO | disclosed |
| US-4478818-A | Ocular preparation housing steroid in two different therapeutic forms | ALZA CORPORATION (US) | 1984-10-23 | — | — | US | disclosed |
| US-4432964-A | Topical composition containing steroid in two forms released independently from polymeric carrier | ALZA CORPORATION (US) | 1984-02-21 | — | — | US | disclosed |
| US-4304765-A | Ocular insert housing steroid in two different therapeutic forms | ALZA CORPORATION (US) | 1981-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240100068-A1 | METHODS COMPRISING ADMINISTRATION OF A GLUCOCORTICOID RECEPTOR AGONIST AND AN INHIBITOR OF CALCINEURIN | PPP3R1, CHP1, NR3C1 | HSD17B10 2855/4885NR3C1 3/4885SERPINA6 69/4885 |
| US-20200390718-A1 | METHODS AND COMPOSITIONS FOR ATTENUATED ANTI-VIRAL TRANSFER VECTOR IMMUNE RESPONSE | HAVCR2, CCL5, IRF3 | HSD17B10 2509/4885NR3C1 30/4885SERPINA6 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.